Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Antibody Cocktail Sweetens Regeneron’s Growth Story

Executive Summary

With REGEN-COV in the mix, Regeneron recorded 51% total revenue growth during Q3, including partnership revenue from Roche, but the product’s long-term viability remains in question.

You may also be interested in...



Regeneron Has Strong Showing, But No REGEN-COV Sales Expected In First Half

Dupixent sales grew by more than 50% as Eylea and REGEN-COV also drove sales growth, though the antiviral advantage will vanish due to the FDA restricting its use.

Could Prevention Data Give REGEN-COV Competitive Leg Up?

Could Prevention Data Give REGEN-COV Competitive Leg Up?

MSD's COVID-19 Pill Molnupiravir Gains First Approval In UK

The UK becomes the first country to grant a marketing authorization for the oral treatment which could help cut hospitalizations and deaths by half.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel